Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Completed

Conditions studied: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy

In brief

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.

Key facts

Study ID

NCT05510908

Run by

AIDS Malignancy Consortium

People needed

460

Starts

2023-07-25

Expected to finish

2025-06-02

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant can understand and is willing to sign a written informed consent document.
• HIV positive. Documentation of HIV-1 infection by means of any one of the following:
• Documentation of an HIV diagnosis in the medical record by a licensed health care provider;
• Documentation of receipt of antiretroviral therapy (ART) (i.e., at least two different medications that do not constitute a prescription for pre-exposure prophylaxis [PrEP]) by a licensed health care provider. Documentation may be a record of an ART prescription in the medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name;
• HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating >1000 RNA copies/mL;
• Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.
• Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).
• WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load.
• Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories:
• New, primary or recurrent diagnosis -Considering or currently receiving cancer treatment
• Metastatic or locally advanced cancer - This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
• Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
• Age ≥ 18 years.
• Participant presents to an AMC domestic clinical trial site for either clinical care or research.

You may not qualify if…

• Participants who do not fulfill the criteria as listed above are ineligible.

Where it is running

• Moores UCSD Cancer Center — La Jolla, California, United States
• George Washington University Cancer Center — Washington D.C., District of Columbia, United States
• University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Weill Cornell Medicine - Cornell Clinical Trials Unit — New York, New York, United States
• Mount Sinai Hospital — New York, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• The Ohio State University — Columbus, Ohio, United States
• Abramson Cancer Center at Pennsylvania Hospital — Philadelphia, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Institute - University of Utah — Salt Lake City, Utah, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• University of Puerto Rico — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.